TIANYU PHARM: Net profit in the third quarter was 71.4211 million yuan, a year-on-year increase of 123.90%Zhitong·Oct 29, 2025 at 06:32 AM300702-0.15%
TIANYU PHARM: Candesartan Cilexetil Tablets have completed drug registrationZhitong·Sep 4, 2025 at 03:12 AM300702-0.15%
TIANYU PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 150 million yuan, an increase of 180.96%Zhitong·Aug 22, 2025 at 07:13 AM300702-0.15%
The A-share chemical pharmaceutical sector continues to rise, with TIBET AIM PHARM hitting the limit up, and TIANYU PHARM, CSBIO, Zhendong Pharmaceutical, Menovo, JENKEM, and GuangShengTang following suitZhitong·Aug 11, 2025 at 12:37 AM688356+0.43%300702-0.15%
TIANYU PHARM signed a cooperation agreement with Heilongjiang Fengyou Biotechnology Development Co., LtdZhitong·Aug 10, 2025 at 11:42 PM300702-0.15%
TIANYU PHARM: The company's bulk lisinopril raw material has obtained the CEP certificateZhitong·Aug 1, 2025 at 05:39 AM300702-0.15%
TIANYU PHARM: Wholly-owned subsidiary's raw materials obtained CEP certificationZhitong·Jul 28, 2025 at 04:30 AM300702-0.15%
TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%Zhitong·Jul 15, 2025 at 04:17 AM300702-0.15%
TIANYU PHARM: Rosuvastatin and Ezetimibe Tablets (I) Obtained Drug Registration CertificateZhitong·Jul 10, 2025 at 08:32 AM300702-0.15%
China Merchants Securities: The trend of innovation going overseas has emerged, and we remain optimistic about opportunities in innovative drugs and pharmaceutical consumptionZhitong·Jun 30, 2025 at 01:54 AM600521+2.45%688166+3.49%
One of the actual controllers of TIANYU PHARM, Tu Shanzeng, plans to reduce his holdings by no more than 3%Zhitong·Jun 25, 2025 at 08:02 AM300702-0.15%
TIANYU PHARM: Montelukast Sodium Tablets have obtained the drug registration certificateZhitong·Jun 13, 2025 at 07:48 AM300702-0.15%
TIANYU PHARM: The active pharmaceutical ingredient of Irbesartan (Process II) has obtained the CEP certificateZhitong·Jun 13, 2025 at 07:46 AM300702-0.15%
SDKX and TIANYU PHARM have reached a strategic cooperationZhitong·Apr 30, 2025 at 08:38 PM688136+3.63%300702-0.15%
Tianfeng Securities: Q1 performance of the raw material drug sector is good, focusing on three main lines: stabilization of API variety prices, integration of formulations, and transformation of new businessesZhitong·Apr 29, 2025 at 06:47 PM603538+3.04%600521+2.45%
